Ability 0 7 0 7 O
to 8 10 8 10 O
swallow 11 18 11 18 O
entrectinib 19 30 19 30 B-treatment
intact 31 37 31 37 O

Active 0 6 38 44 O
gastrointestinal 7 23 45 61 B-chronic_disease
disease 24 31 62 69 I-chronic_disease
or 32 34 70 72 O
other 35 40 73 78 O
malabsorption 41 54 79 92 B-chronic_disease
syndromes 55 64 93 102 I-chronic_disease

At 0 2 103 105 O
least 3 8 106 111 O
2 9 10 112 113 B-lower_bound
weeks 11 16 114 119 I-lower_bound
or 17 19 120 122 O
5 20 21 123 124 O
half 22 26 125 129 O
- 26 27 129 130 O
lives 27 32 130 135 O
, 32 33 135 136 O
whichever 34 43 137 146 O
is 44 46 147 149 O
shorter 47 54 150 157 O
, 54 55 157 158 O
must 56 60 159 163 O
have 61 65 164 168 O
elapsed 66 73 169 176 O
after 74 79 177 182 O
prior 80 85 183 188 B-treatment
chemotherapy 86 98 189 201 I-treatment
or 99 101 202 204 O
small 102 107 205 210 B-treatment
molecule 108 116 211 219 I-treatment
targeted 117 125 220 228 I-treatment
therapy 126 133 229 236 I-treatment

At 0 2 237 239 O
least 3 8 240 245 O
4 9 10 246 247 B-lower_bound
weeks 11 16 248 253 I-lower_bound
must 17 21 254 258 O
have 22 26 259 263 O
elapsed 27 34 264 271 O
since 35 40 272 277 O
completion 41 51 278 288 O
of 52 54 289 291 O
antibody 55 63 292 300 B-treatment
- 63 64 300 301 I-treatment
directed 64 72 301 309 I-treatment
therapy 73 80 310 317 I-treatment

Current 0 7 318 325 O
participation 8 21 326 339 O
in 22 24 340 342 O
another 25 32 343 350 O
therapeutic 33 44 351 362 B-treatment
clinical 45 53 363 371 I-treatment
trial 54 59 372 377 O

Eastern 0 7 378 385 B-clinical_variable
Cooperative 8 19 386 397 I-clinical_variable
Oncology 20 28 398 406 I-clinical_variable
Group 29 34 407 412 I-clinical_variable
( 35 36 413 414 I-clinical_variable
ECOG 36 40 414 418 I-clinical_variable
) 40 41 418 419 I-clinical_variable
performance 42 53 420 431 I-clinical_variable
status 54 60 432 438 I-clinical_variable
≤ 61 62 439 440 O
2 63 64 441 442 B-upper_bound

For 0 3 443 446 O
patients 4 12 447 455 O
enrolled 13 21 456 464 O
via 22 25 465 468 O
local 26 31 469 474 O
molecular 32 41 475 484 O
testing 42 49 485 492 O
, 49 50 492 493 O
an 51 53 494 496 O
archival 54 62 497 505 O
or 63 65 506 508 O
fresh 66 71 509 514 O
tumor 72 77 515 520 B-cancer
tissue 78 84 521 527 O
( 85 86 528 529 O
unless 86 92 529 535 O
medically 93 102 536 545 O
contraindicated 103 118 546 561 O
) 118 119 561 562 O
is 120 122 563 565 O
required 123 131 566 574 O
to 132 134 575 577 O
be 135 137 578 580 O
submitted 138 147 581 590 O
for 148 151 591 594 O
independent 152 163 595 606 O
central 164 171 607 614 O
molecular 172 181 615 624 O
testing 182 189 625 632 O
at 190 192 633 635 O
Ignyta 193 199 636 642 O
's 199 201 642 644 O
CLIA 202 206 645 649 O
laboratory 207 217 650 660 O
post 218 222 661 665 O
- 222 223 665 666 O
enrollment 223 233 666 676 O

History 0 7 677 684 O
of 8 10 685 687 O
additional 11 21 688 698 O
risk 22 26 699 703 O
factors 27 34 704 711 O
for 35 38 712 715 O
torsade 39 46 716 723 B-chronic_disease
de 47 49 724 726 I-chronic_disease
pointes 50 57 727 734 I-chronic_disease

History 0 7 735 742 O
of 8 10 743 745 O
non 11 14 746 749 O
- 14 15 749 750 O
pharmacologically 15 32 750 767 O
induced 33 40 768 775 O
prolonged 41 50 776 785 O
QTc 51 54 786 789 B-clinical_variable
interval 55 63 790 798 I-clinical_variable

History 0 7 799 806 O
of 8 10 807 809 O
other 11 16 810 815 O
previous 17 25 816 824 O
cancer 26 32 825 831 B-cancer
that 33 37 832 836 O
would 38 43 837 842 O
interfere 44 53 843 852 O
with 54 58 853 857 O
the 59 62 858 861 O
determination 63 76 862 875 O
of 77 79 876 878 O
safety 80 86 879 885 O
or 87 89 886 888 O
efficacy 90 98 889 897 O

Incomplete 0 10 898 908 O
recovery 11 19 909 917 O
from 20 24 918 922 O
any 25 28 923 926 O
surgery 29 36 927 934 B-treatment

Known 0 5 935 940 O
active 6 12 941 947 B-chronic_disease
infections 13 23 948 958 I-chronic_disease

Known 0 5 959 964 O
interstitial 6 18 965 977 B-chronic_disease
lung 19 23 978 982 I-chronic_disease
disease 24 31 983 990 I-chronic_disease
, 31 32 990 991 O
interstitial 33 45 992 1004 O
fibrosis 46 54 1005 1013 B-chronic_disease
, 54 55 1013 1014 O
or 56 58 1015 1017 O
history 59 66 1018 1025 O
of 67 69 1026 1028 O
tyrosine 70 78 1029 1037 O
kinase 79 85 1038 1044 O
inhibitor 86 95 1045 1054 O
- 95 96 1054 1055 O
induced 96 103 1055 1062 O
pneumonitis 104 115 1063 1074 B-chronic_disease

Patients 0 8 1075 1083 O
diagnosed 9 18 1084 1093 O
with 19 23 1094 1098 O
anaplastic 24 34 1099 1109 B-cancer
large 35 40 1110 1115 I-cancer
cell 41 45 1116 1120 I-cancer
lymphoma 46 54 1121 1129 I-cancer
( 55 56 1130 1131 I-cancer
ALCL 56 60 1131 1135 I-cancer
) 60 61 1135 1136 I-cancer
harboring 62 71 1137 1146 O
a 72 73 1147 1148 O
gene 74 78 1149 1153 O
rearrangement 79 92 1154 1167 O
of 93 95 1168 1170 O
interest 96 104 1171 1179 O
may 105 108 1180 1183 O
be 109 111 1184 1186 O
eligible 112 120 1187 1195 O

Patients 0 8 1196 1204 O
with 9 13 1205 1209 O
CNS 14 17 1210 1213 O
involvement 18 29 1214 1225 O
, 29 30 1225 1226 O
including 31 40 1227 1236 O
leptomeningeal 41 55 1237 1251 B-cancer
carcinomatosis 56 70 1252 1266 I-cancer
, 70 71 1266 1267 O
which 72 77 1268 1273 O
is 78 80 1274 1276 O
either 81 87 1277 1283 O
asymptomatic 88 100 1284 1296 O
or 101 103 1297 1299 O
previously 104 114 1300 1310 O
- 114 115 1310 1311 O
treated 115 122 1311 1318 O
and 123 126 1319 1322 O
controlled 127 137 1323 1333 O

Peripheral 0 10 1334 1344 B-clinical_variable
neuropathy 11 21 1345 1355 I-clinical_variable
Grade 22 27 1356 1361 I-clinical_variable
≥ 28 29 1362 1363 O
2 30 31 1364 1365 B-lower_bound

Prior 0 5 1366 1371 B-treatment
anticancer 6 16 1372 1382 I-treatment
therapy 17 24 1383 1390 I-treatment

Prior 0 5 1391 1396 B-treatment
treatment 6 15 1397 1406 I-treatment
with 16 20 1407 1411 O
approved 21 29 1412 1420 O
or 30 32 1421 1423 O
investigational 33 48 1424 1439 B-treatment
Trk 49 52 1440 1443 I-treatment
, 52 53 1443 1444 O
ROS1 54 58 1445 1449 B-treatment
, 58 59 1449 1450 O
or 60 62 1451 1453 O
ALK 63 66 1454 1457 B-treatment
inhibitors 67 77 1458 1468 I-treatment
in 78 80 1469 1471 O
patients 81 89 1472 1480 O
who 90 93 1481 1484 O
have 94 98 1485 1489 O
tumors 99 105 1490 1496 B-cancer
that 106 110 1497 1501 O
harbor 111 117 1502 1508 O
those 118 123 1509 1514 O
respective 124 134 1515 1525 O
gene 135 139 1526 1530 O
rearrangements 140 154 1531 1545 O

ROS1 0 4 1546 1550 O
- 4 5 1550 1551 O
rearranged 5 15 1551 1561 O
NSCLC 16 21 1562 1567 B-cancer
patients 22 30 1568 1576 O
presenting 31 41 1577 1587 O
with 42 46 1588 1592 O
CNS 47 50 1593 1596 O
- 50 51 1596 1597 O
only 51 55 1597 1601 O
progression 56 67 1602 1613 O

excluding 0 9 1614 1623 O
approved 10 18 1624 1632 O
or 19 21 1633 1635 O
investigational 22 37 1636 1651 B-treatment
Trk 38 41 1652 1655 I-treatment
, 41 42 1655 1656 O
ROS1 43 47 1657 1661 B-treatment
, 47 48 1661 1662 O
or 49 51 1663 1665 O
ALK 52 55 1666 1669 B-treatment
inhibitors 56 66 1670 1680 I-treatment
in 67 69 1681 1683 O
patients 70 78 1684 1692 O
who 79 82 1693 1696 O
have 83 87 1697 1701 O
tumors 88 94 1702 1708 B-cancer
that 95 99 1709 1713 O
harbor 100 106 1714 1720 O
those 107 112 1721 1726 O
respective 113 123 1727 1737 O
gene 124 128 1738 1742 O
rearrangements 129 143 1743 1757 O

metastatic 0 10 1758 1768 B-cancer
solid 11 16 1769 1774 I-cancer
tumor 17 22 1775 1780 I-cancer
that 23 27 1781 1785 O
harbors 28 35 1786 1793 O
an 36 38 1794 1796 O
NTRK1/2/3 39 48 1797 1806 B-clinical_variable
, 48 49 1806 1807 O
ROS1 50 54 1808 1812 B-clinical_variable
, 54 55 1812 1813 O
or 56 58 1814 1816 O
ALK 59 62 1817 1820 B-cancer
gene 63 67 1821 1825 I-cancer
rearrangement 68 81 1826 1839 I-cancer

minimum 0 7 1840 1847 O
life 8 12 1848 1852 B-clinical_variable
expectancy 13 23 1853 1863 I-clinical_variable
of 24 26 1864 1866 O
4 27 28 1867 1868 B-lower_bound
weeks 29 34 1869 1874 I-lower_bound

prior 0 5 1875 1880 B-treatment
treatment 6 15 1881 1890 I-treatment
with 16 20 1891 1895 I-treatment
crizotinib 21 31 1896 1906 I-treatment
is 32 34 1907 1909 O
permitted 35 44 1910 1919 O
only 45 49 1920 1924 O
in 50 52 1925 1927 O
ALK 53 56 1928 1931 O

prior 0 5 1932 1937 O
treatment 6 15 1938 1947 O
with 16 20 1948 1952 O
crizotinib 21 31 1953 1963 B-treatment
is 32 34 1964 1966 O
permitted 35 44 1967 1976 O
only 45 49 1977 1981 O
in 50 52 1982 1984 O
ALK- 53 57 1985 1989 O
or 58 60 1990 1992 O
ROS1 61 65 1993 1997 O
- 65 66 1997 1998 O
rearranged 66 76 1998 2008 O
NSCLC 77 82 2009 2014 O
patients 83 91 2015 2023 O
presenting 92 102 2024 2034 O
with 103 107 2035 2039 O
CNS 108 111 2040 2043 O
- 111 112 2043 2044 O
only 112 116 2044 2048 O
progression 117 128 2049 2060 O

